CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01399372
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:03.644079+00:00
Published At: 2021-05-13T00:00:00+00:00
Record Updated At: 2023-07-20
Results Posted At: 2021-05-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Lymphoma", "Neurotoxicity", "Radiation Toxicity"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-07-20"
protocolSection.identificationModule.nctId: "NCT01399372"
protocolSection.identificationModule.officialTitle: "Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-05-13"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.